Overview

Delineation of the Role of Glucagon-like Peptide-1 Signalling in Relation to Increased Carbohydrate Content in the Distal Small Intestines

Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
0
Participant gender:
All
Summary
Investigation of GLP-1 signalling in the glucose-lowering effect of increased carbohydrate content in the distal small intestines induced by alpha-glucosidase inhibition during meal ingestion in patients with type 2 diabetes
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University Hospital, Gentofte, Copenhagen
Collaborator:
University of Copenhagen
Treatments:
Acarbose
Glucagon
Glucagon-Like Peptide 1
Criteria
Inclusion Criteria:

- Type 2 diabetes for at least three months (diagnosed according to the criteria of the
World Health Organization (WHO)) treated with metformin monotherapy

- Caucasian ethnicity

- Normal haemoglobin

- Age >18 years

- BMI >23 kg/m2 and <35 kg/m2

- Informed and written consent

Exclusion Criteria:

- Liver disease (alanine aminotransferase (ALAT) and/or serum aspartate aminotransferase
(ASAT) >2 times normal values) or history of hepatobiliary disorder

- Gastrointestinal disease, previous intestinal resection, cholecystectomy or any major
intra-abdominal surgery

- Reduced kidney function or nephropathy (estimated glomerular filtration rate (eGFR)
<60 ml/min/1.73 m2 (based on serum creatinine) and/or albuminuria

- Treatment with medicine that cannot be paused for 12 hours

- Intake of antibiotics two months prior to study

- Treatment with glucose-lowering drugs other than metformin

- Hypo- and hyperthyroidism

- Treatment with oral anticoagulants

- Active or recent malignant disease

- Any treatment or condition requiring acute or sub-acute medical or surgical
intervention

- Lack of effective birth control in premenopausal women

- Positive pregnancy test on study days in premenopausal women

- Pregnancy

- Women who are breastfeeding

- Any condition considered incompatible with participation by the investigators

- If the subjects receive any antibiotic treatment while included in the study they will
be excluded